Leukemia: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
kTidak ada ringkasan suntingan Tag: VisualEditor Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
|||
| (82 revisi perantara oleh 55 pengguna tidak ditampilkan) | |||
Baris 7:
ICDO = 9800-9940 |
Image = acute_leukemia-ALL.jpg |
Caption = Sediaan sumsum tulang dengan pewarnaan Wright. Sediaan
MedlinePlus = |
eMedicineSubj = |
Baris 13:
DiseasesDB = 7431 |
}}
'''Leukemia'''; dalam bahasa Yunani leukos ''[[wikt:λευκός|λευκός]]'', "putih"; aima ''[[wikt:αίμα|αίμα]]'', "darah"), atau lebih dikenal sebagai '''kanker darah'''
|title=Neoplasma Sistem Hematopoietik: Leukemia
|author=Simon, Sumanto, dr. Sp.PK
|publisher=Fakultas Kedokteran Unika Atma Jaya Jakarta
|year=2003}}</ref> [[Sel|Sel-sel]] normal di dalam sumsum tulang digantikan oleh sel tak normal atau abnormal. Sel abnormal ini keluar dari sumsum dan dapat ditemukan di dalam darah perifer atau darah tepi. Sel leukemia memengaruhi hematopoiesis atau proses pembentukan sel darah normal dan imunitas tubuh penderita.
Kata ''leukemia'' berarti [[darah putih]], karena pada penderita ditemukan banyak sel darah putih sebelum diberi terapi. Sel darah putih yang tampak banyak merupakan [[sel]] yang muda, misalnya [[promielosit]]. Jumlah yang
Pada tahun 2000, terdapat sekitar 256.000 anak dan dewasa di seluruh dunia menderita penyakit sejenis leukemia, dan 209.000 orang di antaranya meninggal karena penyakit tersebut.<ref name=Jumlah>{{cite journal
|title=Cancer incidence, mortality and survival by site for 14 regions of the world.
|author=Mathers, Colin D, Cynthia Boschi-Pinto, Alan D Lopez and Christopher JL Murray
|work=Global Programme on Evidence for Health Policy Discussion Paper No. 13
|publisher=World Health Organization
|year=2001
|url=http://www.who.int/entity/healthinfo/paper13.pdf}}</ref> Hampir 90% dari semua penderita yang terdiagnosis adalah dewasa.<ref name=LLS>[http://www.leukemia-lymphoma.org/all_page?item_id=9346 "Leukemia Facts & Statistics."] The Leukemia & Lymphoma Society. Retrieved 2009-07-02.</ref>
== Klasifikasi ==
Baris 25 ⟶ 37:
=== Tipe sel predominan yang terlibat: limfoid dan mieloid ===
Kemudian, penyakit diklasifikasikan dengan jenis sel yang ditemukan pada sediaan darah tepi.
* Ketika leukemia
* Ketika leukemia
=== Jumlah leukosit dalam darah ===
Baris 36 ⟶ 48:
Dengan mengombinasikan dua klasifikasi pertama, maka leukemia dapat dibagi menjadi:
* [[Leukemia limfositik akut]] (LLA) merupakan tipe leukemia paling sering terjadi pada anak-anak. Penyakit ini juga terdapat pada dewasa yang terutama telah berumur 65 tahun atau lebih
* [[Leukemia mielositik akut]] (LMA) lebih sering terjadi pada dewasa daripada anak-anak. Tipe ini dahulunya disebut leukemia nonlimfositik akut.
* [[Leukemia limfositik kronis]] (LLK) sering diderita oleh orang dewasa yang berumur lebih dari 55 tahun. Kadang-kadang juga diderita oleh dewasa muda, dan hampir tidak ada pada anak-anak
* [[Leukemia mielositik kronis]] (LMK) sering terjadi pada orang dewasa. Dapat juga terjadi pada anak-anak,
Tipe yang sering diderita orang dewasa adalah LMA dan LLK, sedangkan LLA sering terjadi pada anak-anak.
Baris 45 ⟶ 57:
Leukemia akut dan kronis merupakan suatu bentuk keganasan atau maligna yang muncul dari perbanyakan klonal sel-sel pembentuk [[sel]] darah yang tidak terkontrol. Mekanisme kontrol seluler normal mungkin tidak bekerja dengan baik akibat adanya perubahan pada kode [[genetika|genetik]] yang seharusnya bertanggung jawab atas pengaturan pertubuhan sel dan diferensiasi.
Sel-sel leukemia menjalani waktu daur ulang yang lebih lambat dibandingkan sel normal. Proses pematangan atau maturasi berjalan tidak lengkap dan
== Etiologi ==
Penyebab leukemia belum diketahui secara pasti,
=== Radiasi ===
Baris 57 ⟶ 69:
=== Faktor leukemogenik ===
Terdapat beberapa zat [[kimia]] yang telah diidentifikasi dapat
* Racun lingkungan seperti [[benzena]]
* Bahan kimia industri seperti [[insektisida]]
Baris 63 ⟶ 75:
=== Epidemiologi ===
* Di [[Afrika]],
* Di [[Kenya]], [[Tiongkok]], dan [[India]], LMK mengenai penderita berumur
* Pada orang [[Asia Timur]] dan [[India]] Timur jarang ditemui LLK.
=== Herediter ===
Penderita [[sindrom Down|sindrom down]] memiliki insidensi leukemia akut 20 kali lebih besar dari orang normal.
=== Virus ===
[[Virus]] dapat menyebabkan leukemia seperti [[retrovirus]], virus leukemia feline, HTLV-1 pada [[dewasa]].
== Penyembuhan ==
Sebagian besar bentuk leukemia diobati dengan obat farmasi, biasanya digabungkan ke dalam sejenis kemoterapi obat-obatan multi. Bisa juga diobati dengan terapi radiasi. Dalam beberapa kasus, pencangkokan sumsum tulang juga dapat menyembuhkan leukemia. Bunga dan daun [[tapak dara]] juga berpotensi menjadi sumber obat untuk leukemia.
== Pengobatan kanker darah ==
Berdasarkan hasil penelitian Dr. M. Ahkam Subroto, tanaman sarang semut mengandung berbagai jenis zat aktif seperti [[flavonoid]], [[tanin]], dan zat lain yang sangat penting bagi tubuh. Kandungan zat flavonoid-nya dipercaya sebagai zat anti-kanker yang mampu melawan sel kanker terutama sel kanker darah sehingga sangat cocok dijadikan sebagai obat tradisional kanker darah.
Zat flavonoid sendiri memiliki kemampuan untuk menonaktifkan zat [[karsinogen]] atau zat penyebab kanker. Perkembangan zat karsinogen tersebut akan dihambat sehingga tidak akan menumbuhkan sel-sel yang abnormal. Kemudian, sel abnormal dalam tubuh dicegah supaya tidak bisa membelah diri. Dengan demikian, sel kanker tidak akan menyebar ke berbagai jaringan dan organ lain di dalam tubuh penderita. Ini merupakan obat tradisional kanker darah yang sangat ampuh untuk mengendalikan laju pembelahan sel-sel kanker di dalam tubuh.
Selain flavonoid, terdapat zat lain bernama tokoferol yang mirip dengan vitamin E dan sangat berguna dalam penyembuhan kanker darah. Zat ini sangat efektif untuk menangkap radikal-radikal bebas yang menjadi penyebab kanker.
Sarang semut sebagai obat tradisional kanker darah bisa menjadi alternatif bagi Anda yang tidak ingin menjalani pengobatan [[kemoterapi]]. Zat-zat yang terkandung dalam sarang semut secara aktif akan membunuh sel-sel kanker dalam tubuh. Para ahli juga menyarankan kepada para penderita kanker darah untuk mengonsumsi tanaman ini secara rutin. Menurut beberapa ahli, pasien yang mengonsumsi sarang semut menunjukkan kemajuan dalam proses penyembuhan dalam waktu beberapa minggu. Bahkan ada di antara mereka yang kondisinya membaik hanya dalam beberapa hari saja setelah mengonsumsi obat tersebut.
== Leukemia akut ==
Baris 80 ⟶ 104:
* Pengeluaran faktor faali yang mengakibatkan [[komplikasi]] yang signifikan
=== Alat
Leukemia akut dapat di[[
* Pemeriksaan fisik, melihat adanya tanda anemia, pembengkakan kelenjar getah bening, dan pembesaran hati serta limpa.
* Tes darah, mengetahui kadar trombisit yang tidak normal.
* Tes sumsum tulang, mengambil sampel dari sumsum tulang untuk mendeteksi adanya sel-sel leukemia.<ref name="Informasi Kesehatan">{{Cite web|url=https://doktersehat.com/leukemia-1/|website=www.doktersehat.com|title=Leukemia: Penyebab, Gejala, Diagnosis dan Pengobatan|language=id|access-date=2020-07-15|archive-date=2020-07-15|archive-url=https://web.archive.org/web/20200715135658/https://doktersehat.com/leukemia-1/|dead-url=yes}}</ref>
<!--
Baris 93 ⟶ 115:
==='''Acute Myelogenous Leukemia (AML)'''===
It is most common for adults, but more men than women are affected.
Many different chemotherapeutic plans are available for the treatment of AML. Overall, the strategy is to control bone marrow and systemic (whole-body) disease while offering specific treatment for the central nervous system (CNS), if involved. In general, most oncologists rely on combinations of drugs for the initial, induction phase of chemotherapy. Such combination chemotherapy usually offers the benefits of early remission (lessening of the disease) and a lower risk of disease resistance. Consolidation or "maintenance" treatments may be given to prevent disease recurrence once remission has been achieved. Consolidation treatment often entails a repetition of induction chemotherapy or the intensification chemotherapy with added drugs. By contrast, maintenance treatment involves drug doses that are lower than those administered during the induction phase.
In addition, specific treatment plans may be used, depending on the type of leukemia that has been diagnosed. Whatever the plan, it is important for the patient to understand the treatment that is being given and the decision-making process behind the choice.
===='''Initial treatment of AML'''====
Baris 101 ⟶ 123:
===='''Follow-up treatment'''====
Follow-up therapy for such patients may involve:
* supportive care, such as intravenous nutrition and treatment with oral antibiotics (e.g., ofloxacin, rifampin), especially in patients who have prolonged granulocytopenia; that is too few mature granulocytes (neutrophils), the bacteria-destroying white blood cells that contain small particles, or granules (< 100 granulocytes per cubic millimeter for 2 weeks)
Baris 107 ⟶ 129:
* transfusions with red blood cells and platelets
Patients with newly diagnosed disease also may be considered for stem cell transplantation (SCT), either from the bone marrow or other sources. Allogeneic bone marrow transplant (alloBMT) is reserved primarily for patients under 55 years of age who have a compatible family donor. Approximately half of newly diagnosed AML patients are in this age group, with 75% achieving a complete remission (CR) after induction and consolidation therapy. Allogeneic bone marrow transplant is available for about 15% of all patients with AML. Unfortunately, it is estimated that only 7% of all AML patients will be cured using this procedure.
People who receive stem cell transplantation (SCT, alloBMT) require protective isolation in the hospital, including filtered air, sterile food, and sterilization of the microorganisms in the gut, until their total white blood cell (WBC) count is above 500.
Treatment of central nervous system leukemia, if present, may involve injection of chemotherapeutic drugs (e.g., cytarabine or ara-C, methotrexate) into the areas around the brain and spinal cord.
====Consolidation or maintenance therapy====
Once the patient is in remission, he or she will receive consolidation or maintenance therapy, for example, consolidation therapy with high-dose ara-C (HDAC) with/without anthracycline drugs).
If, however, the AML patient has resistant disease (about 15%) or relapses (about 70%), second remissions sometimes are achieved by treating them with:
* conventional induction chemotherapy
Baris 122 ⟶ 144:
* etoposide or other single chemotherapeutic agents
Elderly AML patients have special treatment concerns. They may be less able to tolerate the septicemia (blood poisoning) associated with granulocytopenia, and they often have higher rates of myelodysplastic ('preleukemia') syndrome (MDS). Individuals who are over age 75 or who have significant medical conditions can be treated effectively with low-dose ara-C. High-dose post-induction chemotherapy is unlikely to be tolerated by elderly patients.
Until recently, the treatment plans and responses of children with AML did not differ much from those of adults. Yet new, more intensive induction and consolidation treatments have resulted in higher remission rates and prolonged survivals. Many induction trials have produced good results using combinations of cytarabine (ara-C) plus an anthracycline (e.g., daunorubicin, doxorubicin). In children under 3 years of age, the anthracycline used for induction should be chosen with care, since doxorubicin produces more toxicity and related deaths than daunorubicin.
Consolidation therapy is complex, but it should include at least two courses of high-dose ara-C (HDAC). Children who have hyperleukocytosis (too many white blood cells), especially monocytic M5 leukemia, have a poor prognosis.
===Chronic Myelogenous Leukemia (CML)===
The challenge of treating newly diagnosed CML is to determine the best overall strategy to control the disease. General strategies for management include a variety of options:
'''Leukapheresis''', also known as a peripheral blood stem cell transplant, with stem cell cryopreservation (frozen storage) prior to any other treatment. The patient's blood is passed through a machine that removes the stem cells and then returns the blood to the patient. Leukapheresis usually takes 3 or 4 hours to complete. The stem cells may or may not be treated with drugs to kill any cancer cells. The stem cells then are stored until they are transplanted back into the patient.
'''HLA (human leukocyte antigen) typing''' of all patients under age 60, as well as typing of siblings, parents, and children, if available. This procedure will determine whether a compatible donor is available for stem cell transplantation.
'''Pre-treatment fertility measures''' (e.g., cryopreservation of semen prior to treatment; completion of a pregnancy prior to treatment) in young patients who have not completed their families.
''Interferon-alpha (INF-a) therapy'''.
'''Chemotherapy''' with drugs such as hydroxyurea (Hydrea®), busulfan (Myleran®) or imatinib mesylate (Gleevec(tm)).
In general, CML treatment options are divided into two groups: those that do not increase survival and those that do. Chemotherapeutic drugs such as hydroxyurea (Hydrea®) and busulfan (Myleran®) can normalize the blood count for a period of time, but they do not increase survival. They often are used to control blood counts in patients who cannot undergo SCT or who do not respond to interferon therapy because of age or medical considerations.
Gleevec, is one of a new class of cancer drugs that disables an abnormal enzyme in the cancerous cell, kills it, but leaves healthy cells virtually untouched. Other cancer therapies, such as chemotherapy, attack healthy cells as well as cancer cells, leaving patients with unpleasant and often severe side effects.
In June of 2006, the Food and Drug Administration (FDA) approved the oral tyrosine kinase inhibitor dasatinib (Sprycel(tm)) to treat CML that does not respond to other therapy.
One treatment that does impact on CML survival is allogeneic bone marrow transplantation, the use of high dose chemotherapy and radiation followed by infusion of a donor bone marrow. This procedure removes the chromosomal abnormality in a large percentage of patients and for them is curative. In addition, there is treatment with interferon (INF). About 20% to 30% of patients taking interferon show elimination of the abnormal chromosome and improved survival. Recent findings also suggest that low-dose cytarabine (ara-C), in combination with interferon, may be more beneficial than interferon alone. For patients who do not respond to interferon, autologous or allogeneic stem cell transplantation is the only alternative.
Patients with advanced-phase disease may be treated with cytotoxic drugs. For example, individuals showing myeloid transformation may be given drugs that are used to induce remission in AML - that is, daunorubicin and cytarabine, with or without 6-thioguanine or etoposide. Blast cell numbers will be reduced temporarily, but they will increase again within 3 to 6 weeks. Individuals showing lymphoid transformation have a slightly better outlook. They are treated with drugs used in the management of acute lymphocytic leukemia (ALL) - that is, prednisone, vincristine, and daunorubicin, with or without L-asparaginase.
Baris 154 ⟶ 176:
===Acute Lymphocytic Leukemia (ALL)===
Proper management of ALL focuses on control of bone marrow and systemic (whole-body) disease as well as prevention of cancer at other sites, particularly the central nervous system (CNS). In general, ALL treatment is divided into several phases:
'''Induction chemotherapy''' to bring about remission - that is, leukemic cells are no longer found in bone marrow samples. For adult ALL, standard induction plans include prednisone, vincristine, and an anthracycline drug; other drug plans may include L-asparaginase or cyclophosphamide. For children with low-risk ALL, standard therapy usually consists of three drugs (prednisone, L-asparaginase, and vincristine) for the first month of treatment. High-risk children may receive these drugs plus an anthracycline such as daunorubicin.
'''Consolidation therapy''' (1-3 months in adults; 4-8 months in children) to eliminate any leukemia cells that are still "hiding" within the body. A combination of chemotherapeutic drugs is used to keep the remaining leukemia cells from developing resistance. Patients with low- to average-risk ALL receive therapy with antimetabolite drugs such as methotrexate and 6-mercaptopurine (6-MP). High-risk patients receive higher drug doses plus treatment with extra chemotherapeutic agents.
'''CNS prophylaxis''' (preventive therapy) to stop the cancer from spreading to the brain and nervous system. Standard prophylaxis may consist of:
Baris 166 ⟶ 188:
Only children with T-cell leukemia, a high white blood cell count, or leukemia cells in the cerebrospinal fluid (CSF) need to receive cranial irradiation as well as IT therapy.
'''Maintenance treatments''' with chemotherapeutic drugs (e.g., prednisone + vincristine + cyclophosphamide + doxorubicin; methotrexate + 6-MP) to prevent disease recurrence once remission has been achieved. Maintenance therapy usually involves drug doses that are lower than those administered during the induction phase. In children, an intensive 6-month treatment program is needed after induction, followed by 2 years of maintenance chemotherapy.
'''Follow-up therapy''' for ALL patients usually consists of:
Baris 172 ⟶ 194:
* transfusions with red blood cells and platelets
A laboratory test known as [[polymerase chain reaction]] (PCR) is advisable for ALL patients, since it may help to identify specific genetic abnormalities. Such abnormalities have a large impact upon prognosis and, consequently, treatment plans. PCR testing is especially important for patients whose disease is B-cell in type. B-cell ALL usually is not cured by standard ALL therapy. Instead, higher response rates are achieved with the aggressive, cyclophosphamide-based regimens that are used for non-Hodgkin's lymphoma.
Among ALL patients, 3-5% children and 25-50% of adults are positive for the Philadelphia chromosome (Ph1){{Fact|date=February 2007}}. Because these patients have a worse prognosis than other individuals with ALL, many oncologists recommend allogeneic bone marrow transplantation (alloBMT), since remission may be brief following conventional ALL chemotherapy.
People who receive bone marrow transplantation will require protective isolation in the hospital, including filtered air, sterile food, and sterilization of the microorganisms in the gut, until their total white blood cell (WBC) count is above 500.
Recurrent ALL patients usually do not benefit from additional chemotherapy alone. If possible, they should receive re-induction chemotherapy, followed by allogeneic bone marrow transplant (alloBMT).
Alternatively, patients with recurrent ALL may benefit from participation in new clinical trials of alloBMT, immune system agents, and chemotherapeutic agents, or low-dose radiotherapy, if the cancer recurs throughout the body or CNS.
===Chronic Lymphocytic Leukemia (CLL)===
The unpleasant truth is that CLL is probably "incurable" by present treatments. But, fortunately, a large group of CLL patients do not require therapy. Studies suggest that people with Stage A CLL (that is, individuals who have fewer than three areas of enlarged lymphoid tissue) do not benefit from early treatment. They may, in fact, suffer drawbacks because of it. Therefore, most oncologists base CLL treatment upon both the stage and symptoms of the patient.
For example, in older patients (60+ years) who have low-risk early stage disease (Rai Stage 0) a conservative "watch and wait" approach may be taken.
By contrast, older individuals with CLL-related complications or more advanced disease (Rai Stage III or IV) may benefit from chemotherapy and treatment with a corticosteroid (e.g., prednisone, prednisolone).
Corticosteroids are first-line agents for people in whom the immune systems has been altered by CLL. CLL may cause autoimmune syndromes in which the patient's immune system attacks and destroys his or her own blood cells. When the red blood cells are affected, the condition is known as immunohemolytic anemia, characterized by decreased numbers of red blood cells, which may cause fatigue, dizziness, and shortness of breath. When the blood platelets are affected, it is called immune-mediated thrombocytopenia, in which a decreased numbers of platelets may lead to bleeding.
For younger patients who are experiencing symptoms, the physician may consider early chemotherapy, plus allogeneic or autologous bone marrow transplantation (alloBMT; autoBMT).
In general, the indications for treatment are:
* falling hemoglobin or platelet count
Baris 202 ⟶ 224:
====Transformation of CLL to high-grade disease or aggressive non-Hodgkin's lymphoma====
If the patient experiences blood flow problems caused by high numbers of leukemia cells in the circulation, the physician may recommend leukapheresis, also known as apheresis, to separate out white blood cells, prior to chemotherapy.
Symptoms that are related to enlargement of the lymph nodes in one area or an overgrown spleen may be treated by localized, low-dose radiotherapy, or surgical management by splenectomy (removal of the spleen). But if leukemia has invaded the lymph nodes at many different sites, total body irradiation (TBI) may be needed.
====Chemotherapy for CLL====
The chemotherapeutic plans that are used most often for CLL are:
* combination chemotherapy with chlorambucil (Leukeran®) or cyclophosphamide (Cytoxan®) plus a corticosteroid drug such as prednisone, or
* single-agent treatments with nucleoside drugs such as fludarabine, pentostatin, or cladribine (2-chlorodeoxyadenisine; 2-CDA). However, such drugs usually are reserved for cases in which CLL is resistant (unresponsive to treatment) or returns after chemotherapy with chlorambucil or cyclophosphamide.
People with intermediate (Rai Stage I and II) or advanced (Rai Stage III or IV) disease may be helped by participation in a clinical trial. At the present time, clinical trials are being conducted using immunologic compounds (e.g., interferons, monoclonal antibodies) as well as new chemotherapeutic agents (e.g., bryostatin, dolastatin 10, and PSC 83 - a cyclosporine drug given with chemotherapy to overcome drug resistance).
Baris 217 ⟶ 239:
Patients with hairy cell leukemia who are symptom-free typically do not receive immediate treatment. They engage in "watchful waiting" with routine bloodwork and exams every three to six months to monitor disease progression and identify any new symptoms.
Treatment is generally considered necessary when the patient shows signs and symptoms such as low blood cell counts (e.g., infection-fighting neutrophil count below 1.0 K/ul), frequent infections, unexplained bruises, anemia, or fatigue that is significant enough to disrupt the patient's everyday life.
Patients who need treatment, which includes most newly diagnosed HCL cases, usually receive either [[cladribine]] or [[pentostatin]], which are both in a class of chemotherapeutic drugs known as [[purine]] analogs or [[nucleoside]]s. In most cases, one round of treatment will produce a prolonged remission.
Baris 229 ⟶ 251:
-->
==
* [[Metaloproteinase matriks-9]]
== Pranala luar ==
* {{en}} [http://www.about-leukemia.com/html/causes.php3 The Causes of Leukemia and Potential Risk Factors] {{Webarchive|url=https://web.archive.org/web/20070521202227/http://www.about-leukemia.com/html/causes.php3 |date=2007-05-21 }}
* {{en}} [http://www.faqs.org/health/Sick-V3/Leukemia.html Federation of American Scientists]
* {{en}} [http://www.lls.org Leukemia and Lymphoma Society]
* {{en}} [http://leukemia.acor.org Association of Cancer Online Resources (ACOR) Leukemia Links] {{Webarchive|url=https://web.archive.org/web/20070224145506/http://leukemia.acor.org/ |date=2007-02-24 }}
* {{en}} [http://www.leukemia-research.org Leukemia Research Foundation] {{Webarchive|url=https://web.archive.org/web/20210325072740/http://www.leukemia-research.org/ |date=2021-03-25 }}
== Referensi ==
{{reflist}}
[[Kategori:Kanker]]
[[Kategori:Hematologi]]
▲[[en:Leukemia]]
| |||